Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the present study is to explore the importance of migraine phenotype on the headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.

NCT00358839

Familial Hemiplegic Migraine

COMPLETED NA

Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide

NCT07021859

Migraine Aura Migraine With Aura

RECRUITING NA

CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment

NCT03481400

Migraine

UNKNOWN NA

Clinical Characteristics and Pathophysiology of Post-Traumatic Headache

NCT03791515

Post-Traumatic Headache Concussion, Mild

COMPLETED NA

Functional MRI (fMRI) in CGRP Induced Migraine

NCT00363532

Migraine Without Aura

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Calcitonin gene-related peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in a large proportion of migraine sufferers. Treatment of spontaneous migraine attacks with an inhibitor of CGRP is effective in many patients. These data show that CGRP is involved in migraine pathophysiology.

The importance of migraine genetics is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Familial Hemiplegic Migraine Migraine With Aura Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

MA-patients

Group Type EXPERIMENTAL

CGRP

Intervention Type DRUG

CGRP (0.5 ug/min) infused intravenously over 20 min

2

FHM-patients

Group Type EXPERIMENTAL

CGRP

Intervention Type DRUG

CGRP (0.5 ug/min) infused intravenously over 20 min

3

Healthy controls

Group Type ACTIVE_COMPARATOR

CGRP

Intervention Type DRUG

CGRP (0.5 ug/min) infused intravenously over 20 min

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CGRP

CGRP (0.5 ug/min) infused intravenously over 20 min

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of familial hemiplegic migraine (IHS-classification criteria)
* Diagnosis of migraine with aura(IHS-classification criteria)
* Healthy controls

Exclusion Criteria

Patients and controls:

* A history of cerebrovascular disease and other CNS- disease
* A history of serious somatic and mental disease
* A history suggesting ischaemic heart disease
* A history of hypo- or hypertension
* Daily intake of medication apart from oral contraceptives
* Abuse of alcohol or medicine (opioid analgesics).
* Pregnant or breastfeeding women.
* On the study day:

* No intake of a simple analgesic in the previous 48 hours
* No headache in the previous 48 hours

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes